Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2009 - 2026)

Biomarin Pharmaceutical has disclosed Other Operating Expenses across 18 years of filings, most recently posting $4.0 million for Q1 2026.

• Quarterly Other Operating Expenses rose 302.71% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 636.91% YoY) and the FY2025 annual result came in at $9.0 million, up 292.74% from the prior year.
• Other Operating Expenses retreated to $4.0 million in Q1 2026, from $9.0 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $111.9 million in Q4 2022 and troughed at -$19.9 million in Q4 2023.
• A 5-year average of $8.0 million and a median of $1.3 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 1172.02% — and 2023, when it sank 1103.38%.
• Tracing BMRN's Other Operating Expenses over 5 years: stood at $111.9 million in 2022, then tumbled by 117.78% to -$19.9 million in 2023, then soared by 65.47% to -$6.9 million in 2024, then jumped by 230.94% to $9.0 million in 2025, then tumbled by 55.97% to $4.0 million in 2026.
• Business Quant data shows BMRN's Other Operating Expenses at $4.0 million in Q1 2026, $9.0 million in Q4 2025, and $5.1 million in Q3 2025.